新型非甾体类盐皮质激素受体拮抗剂在糖尿病肾脏疾病中的疗效与安全性:随机对照试验的最新系统评价与荟萃分析。
完整摘要 · 中文译文
目的:评价新型非甾体类盐皮质激素受体拮抗剂(nsMRAs)在糖尿病肾脏病(DKD)中的疗效与安全性。 方法:遵循PRISMA 2020,我们检索了截至2026年7月31日的四个数据库,纳入在成人DKD患者中比较nsMRAs与安慰剂的随机对照试验(RCTs)。合并估计采用随机效应模型,连续结局使用均数差(MDs),二分类结局使用比值比(ORs),均附95%置信区间(CIs)。偏倚风险采用Cochrane RoB 2评估,证据确定性采用GRADE评估。 结果:共纳入8项RCTs(15,143例患者)。nsMRAs降低了经对数转换的UACR(MD -0.36 log mg/g,95% CI -0.44至-0.28;n = 14,512,来自8项试验,主要由finerenone驱动(8项试验中的5项),药物类型交互作用显著;P < 0.00001)和收缩压(MD -4.72 mmHg,95% CI -8.64至-0.80;n = 7,538,来自3项试验(6项试验报告了收缩压;仅3项可合并);主要由FIGARO-DKD驱动;P = 0.02),但升高了血清钾(MD 0.22 mmol/L,95% CI 0.16至0.29;n = 1,468,来自4项试验(6项试验报告了血清钾;FIDELIO-DKD和FIGARO-DKD被排除);P < 0.00001),并引起早期eGFR下降(MD -3.01 mL/min/1.73 m2,95% CI -4.46至-1.56;n = 1,218,来自3项试验;P < 0.0001)。高钾血症风险更高(OR 2.24,95% CI 1.99至2.52;n = 14,734,来自6项试验;P < 0.00001),而总体不良事件、eGFR下降和急性肾损伤无差异。GRADE证据确定性对于UACR、收缩压、血清钾和早期eGFR下降为低, 和高钾血症为中等确定性。 结论:在糖尿病肾脏病(DKD)中,非甾体类盐皮质激素受体拮抗剂(nsMRA)可能降低尿白蛋白肌酐比值(UACR)和收缩压。然而,UACR结果主要由非奈利酮驱动且存在显著的药物类型交互作用,需按具体药物分别解读。收缩压结果主要由FIGARO-DKD试验驱动。此外,nsMRA可能升高血钾及高钾血症风险,尽管血钾分析排除了两项大型试验。nsMRA还可能导致早期血流动力学估算肾小球滤过率(eGFR)下降。值得注意的是,本综述仅评估了替代终点和安全性结局。若干结局仅由3-4项试验支持。鉴于这些局限性及低至中等确定性,研究结果需谨慎解读并进行风险-获益评估。 系统综述注册:https://www.crd.york.ac.uk/PROSPERO/view/CRD420251072300,注册号CRD420251072300。
完整摘要 · 英文原文
AIMS: To evaluate the efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in diabetic kidney disease (DKD). METHODS: Following PRISMA 2020, we searched four databases to 31 July 2026, for randomized controlled trials (RCTs) comparing nsMRAs with placebo in adults with DKD. Pooled estimates used random-effects models, with mean differences (MDs) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes, each with 95% confidence intervals (CIs). Risk of bias was assessed with Cochrane RoB 2, and certainty of evidence with GRADE. RESULTS: Eight RCTs (15,143 patients) were included. nsMRAs reduced log-transformed UACR (MD -0.36 log mg/g, 95% CI -0.44 to -0.28; n = 14,512 from 8 trials, predominantly driven by finerenone (5 of 8 trials), with significant drug-type interaction; P < 0.00001) and systolic BP (MD -4.72 mmHg, 95% CI -8.64 to -0.80; n = 7,538 from 3 trials (6 trials reported systolic BP; only 3 were poolable); predominantly driven by FIGARO-DKD; P = 0.02), but increased serum potassium (MD 0.22 mmol/L, 95% CI 0.16 to 0.29; n = 1,468 from 4 trials (6 trials reported serum potassium; FIDELIO-DKD and FIGARO-DKD excluded); P < 0.00001) and induced early eGFR decline (MD -3.01 mL/min/1.73 m2, 95% CI -4.46 to -1.56; n = 1,218 from 3 trials; P < 0.0001). Hyperkalemia risk was higher (OR 2.24, 95% CI 1.99 to 2.52; n = 14,734 from 6 trials; P < 0.00001), whereas overall adverse events, eGFR decline, and acute kidney injury did not differ. GRADE certainty was low for UACR, systolic BP, serum potassium, and early eGFR decline, and moderate for hyperkalemia. CONCLUSION: In DKD, nsMRAs may reduce UACR and systolic BP. However, UACR was driven by finerenone with significant drug-type interaction, requiring agent-specific interpretation. Systolic BP was driven by FIGARO-DKD. Furthermore, nsMRAs may increase serum potassium and hyperkalemia risk, although the serum potassium analysis excluded two large trials. nsMRAs may also cause early hemodynamic eGFR decline. Notably, this review assessed only surrogate endpoints and safety outcomes. Several outcomes were supported by only 3-4 trials. Given these limitations and low-to-moderate certainty, findings warrant cautious interpretation and risk-benefit assessment. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251072300, identifier CRD420251072300.